Trial Profile

Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adagrasib (Primary) ; BBP 398 (Primary) ; Cetuximab (Primary)
Indications Adenocarcinoma; Biliary cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Bristol-Myers Squibb

Most Recent Events

07 Jun 2024 Status changed from active, no longer recruiting to discontinued because business objectives have changed.
02 Apr 2024 Planned End Date changed from 25 Jul 2029 to 14 May 2024.
02 Apr 2024 Planned primary completion date changed from 5 Aug 2027 to 14 May 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com